CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 1A 2 COHORT, SINGLE DOSE, OPEN-LABEL, RANDOMIZED, PIVOTAL 
BIOEQUIVALENCE STUDY TO QUALIFY MANUFACTURING SITE TRANSFER 
FROM BARCELONETA TO ASCOLI FOR PRAZOSIN HYDROCHLORIDE 
CAPSULES IN HEALTHY ADULT PARTICIPANTS UNDER FASTED 
CONDITIONS
Study Intervention Number: CP-012299
Study Intervention Name: Prazosin Hydrochloride Capsules
US IND Number:EudraCT Number:ClinicalTrials.gov ID: Not Applicable
Protocol Number: A0281006
Phase: 1
Brief Title:
Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer of Prazosin 
Hydrochloride Capsules
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.
CCI
CCI
CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date Summary of Changes and 
Rationale
Original protocol 22February2021 Not Applicable

CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....7
1. PROTOCOL  SUMMARY.....................................................................................................8
1.1. Synopsis .................................................................................................................. ..8
1.2. Schema (Not Applicable) ........................................................................................121.3. Schedule of Activities .............................................................................................13
2. INTRODUCTION ...............................................................................................................1 6
2.2. Background .............................................................................................................16
2.2.1. Clinical Overview.......................................................................................16
2.3. Benefit/Risk Assessment.........................................................................................17
2.3.1. Risk Assessment .........................................................................................182.3.2. Overall Benefit/Risk Conclusion................................................................19
3. OBJECTIVES AND ENDPOINTS .....................................................................................194. STUDY DESIGN................................................................................................................ .19
4.1. Overall Design.........................................................................................................194.2. Scientific Rationale for Study Design.....................................................................21
4.2.1. Choice of Contraception/Barrier Requirements .........................................214.2.2. Collection of Retained Research Samples..................................................21
4.4. End of Study Definition ..........................................................................................22
5. STUDY POPULATION ......................................................................................................22
5.1. Inclusio n Criteria.....................................................................................................23
5.2. Exclusion Criteria....................................................................................................235.3. Lifestyle Cons iderations..........................................................................................25
5.3.1. Meals and Dietary Restrictions...................................................................255.3.2. Caffeine, Alcohol, and Tobacco .................................................................265.3.3. Activity .......................................................................................................265.3.4. Contraception..............................................................................................27
5.4. Screen Failures ........................................................................................................27
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY .................................27CCI
CCI
CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 46.1. Study  Intervention(s) Administered ........................................................................27
6.1.1. Administration ............................................................................................27
6.2. Preparation, Handling, Storage, and Accountability ...............................................28
6.2.1. Preparation and Dispensing ........................................................................29
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................29
6.3.1. Allocation to Study Intervention ................................................................29
6.4. Study  Intervention Compliance ...............................................................................29
6.5. Dose Modification ...................................................................................................30
6.6. Continued Access to Study  Intervention After the End of the Study ......................30
6.7. Treatment of Overdose
............................................................................................30
6.8. Concomitant Therapy ..............................................................................................30
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................31
7.1. Discontinuation of Study  Intervention ....................................................................31
7.2. Participant Discontinuation/Withdrawal From the Study .......................................31
7.2.1. Withdrawal of Consent ...............................................................................32
7.3. L ost to Follow up
....................................................................................................32
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................33
8.1. Efficacy  Assessments ..............................................................................................34
8.2. Safet y Assessments .................................................................................................34
8.2.1. Phy sical Examinations ................................................................................34
8.2.2. Vital Signs ..................................................................................................35
8.2.3. Electrocardiograms
.....................................................................................35
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................36
8.2.5. COVID -19 specific assessments ................................ ................................ .36
8.2.6. Pregnancy  Testing ......................................................................................37
8.3. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................37
8.3.1. Time Period and Frequency  forCollecting AE and SAE Information .......37
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................38
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
...................38
8.3.2. Method of Detecting AEs and SAEs ................................ .......................... 38
8.3.3. Follow -Up of AEs and SAEs ......................................................................38

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 58.3.4. Regulatory Reporting Requirements for SAEs ...........................................39
8.3.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................39
8.3.5.1. Exposure During Pregnancy ......................................................39
8.3.5.2. Exposure During B reastfeeding ................................................41
8.3.5.3. Occupational Exposure .............................................................41
8.3.6. Cardiovascular and Death Events ...............................................................42
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................42
8.3.8. Adverse Events of Special Interest
.............................................................42
8.3.8.1. Lack of Efficacy ........................................................................42
8.3.9. Medical Device Deficiencies ......................................................................42
8.3.10. Medication Errors .....................................................................................42
8.4. Pha rmacokinetics ....................................................................................................43
8.5.Genetics ...................................................................................................................44
8.5.1. Specified Genetics ......................................................................................44
8.5.2. Retained Research Samples for Genetics
...................................................44
8.6. Biomarkers ..............................................................................................................44
8.7. I mmunogenicit y Assessments .................................................................................44
8.8. Health Economics ...................................................................................................44
9. STATI STICAL CONSI DERATIONS
................................................................................44
9.1. Statistical Hy potheses .............................................................................................44
9.2. Analy sis Sets ...........................................................................................................45
9.3. Statistical Analy ses.................................................................................................45
9.3.1. Primary  Endpoint(s) ................................ ................................ .................... 45
9.3.1.1. Determination of Pharmacokinetic Parameters.........................45
9.3.2. Statistical Analy sis of Pharmacokinetic Parameter
................................ ....46
9.3.3. Safet y anal yses............................................................................................47
9.3.4. Other Anal yse(s).........................................................................................47
9.4. I nterim Anal yses.....................................................................................................48
9.5. Sample Size Determination ................................ ................................ ..................... 48

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 610. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS ................................ ................................ ................................ .......... 49
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............49
10.1.1. Regulatory and Ethical Considerations ....................................................49
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................49
10.1.2. Financial Disclosure .................................................................................50
10.1.3. I nformed Consent Process ........................................................................50
10.1.4. Data Protection .........................................................................................51
10.1.5. Committees Structure ...............................................................................51
10.1.5.1. Data Monitoring Committee ...................................................51
10.1.6. Dissemination of Clinical Study  Data ......................................................51
10.1.7. Data Qualit y Assurance ............................................................................53
10.1.8. Source Documents ....................................................................................54
10.1.9. Study  and Site Start and Closure ..............................................................54
10.1.10. Publication 
Policy ...................................................................................55
10.1.11. Sponsor’s Qualified Medical Personnel .................................................56
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................57
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................58
10.3.1. Definition of AE .......................................................................................58
10.3.2. Definition of an SAE ................................................................................59
10.3.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................60
10.3.4. Reporting of SAEs
....................................................................................64
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................65
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................65
10.4.2. Female Participant Reproductive Inclusion Criteria .................................65
10.4.3. Woman of Childbearing Potential ................................ ............................ 66
10.4.4. Contraception Methods ................................ ................................ ............. 67
10.5. Appendix 5: Genetics ............................................................................................69
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments .......70
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................72

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 710.8. Appendix 8: Alternative Measures During Public Emergencies ..........................74
10.8.1. Study  Intervention ....................................................................................74
10.8.2. Adverse Events and Serious Adverse Events ...........................................74
10.10. Appendix 9: Abbreviations
.................................................................................75
11. REFERENCES ..................................................................................................................78
LIST OF TABLES
Table 1. Schedule of Activities ...............................................................................13
Table 2. Sequences for Cohort 1 .............................................................................20
Table 3. Sequences for Cohort 2 .............................................................................20
Table 4. Composition of 1 mg , 2 mg, and 5 mg Prazosin HCl Capsules 
Manufactured at Ascoli .............................................................................21
Table 5. PK Parameters ..........................................................................................46
Table 6. Protocol -Required Safet y Laboratory  Assessments .................................57

CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 81. PROTOCOL SUMMARY 
1.1. Synopsis Brief Title: Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for 
Prazosin Hydrochloride Capsules.
Background and Rationale:
 
Prazosin is a selective 
α-adrenoreceptor antagonist and is used either as single drug or combination treatment with 
diuretic and/or other antihypertensive drugs for proper patient response.
 
 
 
 
 
 
 
 
 CCI
CCICCI
CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 9Objectives and Endpoints
Objectives Endpoints
Prim ary: Primary: 
To demonstrate bioequivalence betw een 
prazosin HCl 1 and 2 mg capsules 
manufactured at the proposed site (Ascoli) 
versus prazosin HCl 2 mg capsules 
manufactured at current site (Barceloneta) 
under fasting conditions in healthy adult 
participants. 
To demonstrate bioequivalence betw een 
prazosin HCl 5 mg capsules manufactured at 
the proposed site (Ascoli) v ersusprazosin HCl
5 mg capsules manufactured at current site 
(Barceloneta) under fasting conditions in 
healthy adult participants.AUC lastand C maxof prazosin.
Secondary: Secondary: 
To evaluate the safety and tolerability of 
prazosin HCl capsules.AUC inf(if data perm it), t ½(if data permit) and 
Tmaxof prazosin.
Adverse events (AEs).

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 10Overall Design
This study  will be a 2 Cohort, open-label, randomized, single dose stud y in healthy adult 
male and/or female participants. Cohort 1 will be crossover with 3 treatments, 3 periods, 
6sequences. Cohort 2 will be crossover with 2 treatments, 2 periods, 2 sequences.
Approximately  36 participants will be enrolled in each 
Cohort 1 and Cohort 2.Participants 
enrolled in Cohort 1 will not be eligible for Cohort 2 and vice versa. Dropouts for non- safety  
reasons may  be replaced at the discretion of the sponsor and investigator. Participants in 
Cohort 1 will be assigned to 1 of the 6 sequences according to a computer --generated 
randomization schedule and participants in Cohort 2 will be assigned to 1 of the 2 sequences 
according to a computer -generated randomization schedule. The sequences for Cohort 1 and 
Cohort 2 are shown in the tables below.
Sequences for Cohort 1
Sequence N Period 1 Washout 
PeriodPeriod 2 Washout 
PeriodPeriod 3
1 6 Treatment A At least
7 daysTreatment B At least
7 daysTreatment C
2 6 Treatment B Treatment C Treatment A
3 6 Treatment C Treatment A Treatment B
4 6 Treatment A Treatment C Treatment B
5 6 Treatment B Treatment A Treatment C
6 6 Treatment C Treatment B Treatment A
Treatment A: Prazosin HCl 1 x 2 mg capsule manufactured at the current site (Barceloneta) under fasting 
conditions (Reference).
Treatment B: Prazosin HCl 1 x 2 mg capsule manufactured at the proposed site (Ascoli) under fasting 
conditions (Test1).
Treatment C: Prazosin HCl 2 x 1 mg capsule manufactured at the proposed site (Ascoli) under fasting 
conditions (Test2 ).
Sequences for Cohort 2
Sequence N Period 1 Washout Period Period 2
1 18 Treatment D At least 7 days Treatment E
2 18 Treatment E Treatment D
Treatment D: Prazosin HCl 1 x 5 mg capsule manufactured at the current site (Barceloneta) under fasting 
conditions (Reference).
Treatment E : Prazosin HCl 1 x 5 mg capsule manufactured at the proposed site (Ascoli) under fasting 
conditions (Test).
Number of Participants
Approximately  36 participants will be enrolled in each Cohort 1 and Cohort 2such that 30 
evaluable participants complete Cohort 1 and 32 evaluable participants complete Cohort 2.
See the Section 9 .5Sample Size Determination for further details. 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 11Intervention Groups and Duration
Participants will be screened within 28 day s prior to the first dose of study  intervention to 
confirm that they  meet the participant selection criteria for the study .Eligible participants 
will be admitted to the c linical research unit (CRU) on Day  -1 and will remain confined in 
the CRU for approximately  3 day s and 2 nights during each period until the collection of the 
24 hour pharmacokinetic (PK) sample.
On Day  1 of each period, participants will receive a single dose of investigational product as 
per randomization schedule. Study treatments will be administered with approximately  240 
mL of ambient temperature water under fasting conditions (overnight fast and no food until 4 
hours after dosing). W
ater will be allowed without restriction until 1 hour prior to dosing and
may be consumed without restriction beginning 1 hour after dosing.
Blood samples for the analy sis of prazosin in plasma will be obtained predose (immediatel y 
prior to dosing) and postdose. Tolerability  and safety  will be assessed for all treatments by  
monitoring adverse events ( AEs).
There will be a minimum 7 -day washout period between successive doses (ie, administration 
of subsequent doses of study  medication will not occur until at least 7 day s after the previous 
dose of study  medication). The total duration o f participation from the Screening Visit to 
Discharge will be approxim ately 6 weeks , and from the Screening Visit to Follow -up will be 
approxim ately11 weeks.
Study Treatments
For this study , the investigational product is prazosin HCl capsule s.
Prazosin H Cl 2 mg and 5 mg capsules, manufactured at Pfizer Pharmaceutical, Barceloneta 
Puerto Rico are reference treatments. Prazosin HCl 1 mg, 2 mg and 5 mg capsules, 
manufactured at Pfizer Pharmaceutical, Ascoli, Italy  are test treatments. 
Data Monitoring Commit teeor Other Inde pendent Oversight Committee :No
This study  will not use a data monitoring committee (DMC).
Statistical Methods
Pharmacokinetic and statistical analy sis will be performed for prazosin. Data from 2 Cohort s 
will be anal yzed separately . The PK parameters area under the plasma concentration -time 
curve from time zero to the time of the last quantifiable concentration (AUC last), area under 
the plasma 
concentration -time curve from time zero extrapolated to infinite time (AUC inf), 
maximum plasma concentration (Cmax), time to first occurrence of C max(Tmax), and terminal 
phase elimination half-life (t ½)will be summarized descriptivel y by anal yte and treatment.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 12Natural log transformed PK parameters ( AUC inf,AUC last, and C max) will be anal yzed using a 
mixed effect model with sequence, period and treatment as fixed effects and participan t 
within sequence as a random effect. Estimates of the adjusted mean differences 
(Test –Reference) and the corresponding 90% confidence intervals will be obtained from the 
model. The adjusted mean differences and the 90% confidence intervals for the differences 
will be exponentiated to provide estimates of the ratio of adjusted geometric means 
(Test/Reference) and the 90% confidence intervals for the ratios.
For primary  objective, b ioequivalence of the Test treatment relative to Reference treatment 
will be concluded if the 90% confidence intervals (CI) for the ratio of adjusted geometric 
means of Test treatment srelative to Reference treatment for AUC inf(if data permit), AUC last
and C max, fall wholly  within (80%, 125%).
1.2.Schema (Not Applicable)

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 131.3. S chedule of Activ ities
The SoA table (Table 1)provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well -being of the participant. 
Table 1. Schedule of Activities
Visit Identifier Screening 
(Day -
28 to 
Day -2)Periods 1, 2 and 3iEarly 
Termination/
Discontinuatio
n (DC)Follow -upg
Day -1 Day 1 Day 2 28-35 Days
Hours Post Dose 00.25 0.5 0.75 11.5 22.5 33.5 4 6 810 12 24
Informed consent Xa
CRU confinement X                X
Inclusion/exclusion 
criteriaX X
Medical/ medication
history (update)X Xb
Physical exam, height, 
and weightcX X X
Safety laboratory X XhX
Demography X
Pregnancy test (β-hCG )
in WOCBPX X X X
Contraception check X X XhX X
FSHdX
Urine drug testing X X
Supine 12 -Lead single 
ECGX XhX
Vital Signs
(Supine b lood pressure 
and pulse rate )X X XhX

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 14Table 1. Schedule of Activities
Visit Identifier Screening 
(Day -
28 to 
Day -2)Periods 1, 2 and 3iEarly 
Termination/
Discontinuatio
n (DC)Follow -upg
Day -1 Day 1 Day 2 28-35 Days
Hours Post Dose 00.25 0.5 0.75 11.5 22.5 33.5 4 6 810 12 24
HBcAb, HBsAb, 
HBsAg, HCVAb, and 
HIVX
COVID -19 
questionnairekX X
COVID -19 testinglX X
COVID -19 check 
temperaturemX X X X X X X X X X X X X X X X X X X X
Study treatment 
administrationX
Pharmacokinetic blood 
samplin gXeX X X X X X X X X X X X X X X X
Pfizer Prep D1 banked 
samplejX
Serious and nonserious 
Adverse event 
monitoringX                  X X
Concomitant 
treatments X              X X X
CRU dischargefX

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 15Table 1. Schedule of Activities
Visit Identifier Screening 
(Day -
28 to 
Day -2)Periods 1, 2 and 3iEarly 
Termination/
Discontinuatio
n (DC)Follow -upg
Day -1 Day 1 Day 2 28-35 Days
Hours Post Dose 00.25 0.5 0.75 11.5 22.5 33.5 4 6 810 12 24
a. Must be completed before any study related procedures are performed.
b. Period 1 -review changes in medical history since screening. Period 2 & 3 (for Cohort 1) and Period 2 (for Cohort 2) – review changes in medical history since prior 
period.
c. Physical examination, including height and weight, at screening; brief physical examination on Day -1 of Period 1.The screening physical examination may be deferred 
to Day -1 of Period 1;however, height and weight must be done at screening to obtain BMI for determination of eligibility.
d. Females who are amenorrheic for at least 12 consecutive months.
e. Timepoint 0 PK blood sample will be collected predose (within 30 minutes prior to dosing).
f. Participants will be discharged after collection of the 24 -hour PK sample. Participants may remain at the CRU between study periods at the discretion of the investigator.
g. Contact may occur via telephone contact and must occur 28 to 35 days from administration of the final dose of investigational product.
h. At Period 3 only for Cohort -1 and Peri od-2 only for Cohort - 2.
i. Period 1, 2 and 3 for Cohort 1 and Period 1 and 2 for Cohort 2. 
j. Period 1 only. Prep D1 Retained Research Samples for Genetics. If not collected on designated collection day, collect at the next available time point when biospecimens 
are collected in conjunction with a participant visit.
k. Check exposure to positive subject, residence or travel in area of high incidence and COVID -19 related signs and symptoms. To be done at least 48 hours before and at 
each visit.
l. The testin g for COVID -19 pathogen by PCR will be performed at each visit. For participants admitted for residence, a subsequent COVID -19 test will be performed after 
4 days (ie, upon completion of 4 x 24 hours in house), or if they develop COVID -19 like symptom.
m. To be done at least daily during residence.

CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 162. INTRODUCTION
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. Background 
2.2.1. Clinical OverviewPrazosin hydrochloride (HCl) is an oral anti-hypertensive indicated for the treatment of 
primary and secondary hypertension and heart failure. Prazosin is a selective 
α-adrenoreceptor antagonist and is used either as single drug or combination treatment with 
diuretic and/or other antihypertensive drugs for proper patient response.
1
The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Animal studies have suggested that the vasodilator effect 
of prazosin is also related to blockade of postsynaptic α-adrenoceptors. The results of dog 
forelimb experiments demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional 
α-blockers, the antihypertensive action of prazosin is usually not accompanied by reflex
tachycardia. Tolerance has not been observed to develop in long term therapy.
1
Hemodynamic studies have been carried out in man following acute single dose administration and during the course of long term maintenance therapy. The results confirm that the therapeutic effect is a fall in blood pressure unaccompanied by a clinically significant CCI
CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 17change in cardiac output, heart rate, renal blood flow and glomerular filtration rate. There is 
no measurable negative chronotropic effec t.In clinical studies to date, prazosin 
hydrochloride has not increased plasma renin activity .1
In man, blood pressure is lowered in both the supine an d standing positions. The effect is 
most pronounced on the diastolic blood pressure.
Prazosin HCl capsule formulation are available in strengths of 1 mg, 2 mg and 5 mg 
prazosin.1
Following oral administration of prazosin capsules, prazosin is readi ly absorbed from 
gastrointestinal track, Cmaxreach in 1 to 3 hour post dose with a plasma half -life of 2 to 
3 hours . The absolute bioavailability of prazosin in adult humans ranging from 43.5% to 
69.3%.2The rate of absorption of prazosin may  be affected b y the t ype of pharmaceutical 
formulation used, but not its extent.2
Following oral administration of a 5 mg prazosin capsule, reported Cmaxof 35.9 ±
17.3 ng/mL 
occurr ed in 1 to 3 hours post dose.2The pharmacokinetics (PK) of prazosin is linear for both 
area under curve ( AUC )and Cmaxacross the dose range of 0.5 mg to 10 mg.3Food has no 
influence on either rate or extent of drug absorption.2
Prazosin
is highly  bound to plasma protein with plasm a protein binding 97%. The volume 
of distribution following intravenous (IV) administration is approximately  42 liter (L) .2
Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by 
demethy lation and conjug ation, and excreted mainly via bile and urine. Less extensive human 
studies suggest similar metabolism and excretion in man. The total body  clearance of prazosin 
ranged from approximately  10 to 14 L /h.2
Prazosin is a well tolera ted drug with an established safet y profile. Product is contraindicated 
in patients with known sensitivity  to quinazolines, prazosin hy drochloride. T he most frequent 
adverse effect associated with prazosin hy drochloride therap y are dizziness 10.3%, headach e 
7.8%, drowsiness 7.6%, lack of energy  6.9%, weakness 6.5%, palpitations 5.3%, and nausea 
4.9%. In most instances, side effects have disappeared with continued therapy  or have been 
tolerated with no decrease in dose of drug.1
2.3.Benefit/Risk Assessment
Prazosin HCl capsule is not expected to provide any  clinical benefit to healthy  participants. 
This study  is designed primarily  to generate pharmac okinetic and safet y data to support 
regulatory  registration of prazosin HCl capsules at 1 mg, 2 mg and 5 mg strength 
manufactured at Pfizer Ascoli.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected adverse e vents of prazosin HCl capsules may be found in the Minipress® United 
States Package Insert (USPI ) which is the single reference safety  document (SRSD) for this 
study .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 182.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) :Prazosin HCl capsule
Potential risks associated with prazosin 
HCl capsules include the following: 
Dizziness (vertigo), headache, drowsiness, 
lack of energy , weakness, nausea and 
palpitations. These risks represent AEs of 
special interest for with prazosin HCl
capsules (see Section 8.3.8 ).The potential risks are based on product 
labeling for prazosin HCl capsules .AEs and clinical laboratory  results will 
be monitored on an ongoing basis. 
Instructions for managing potential cases 
of DILI are provided (see Appendix 6).
Other
The COVID -19 pandemic may  pose risks 
to study  participation.Participants may  have increased risk of 
SARS -CoV -2 infection by undergoing a 
study  procedure at a study  facility .Inclusion of COVID -19 specific 
assessments according to the Schedule of 
Activities.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 192.3.2. Overall Benefit /Risk Conclusion
Taking into account the measures to minimize risk to study participants, prazosin HCl 
capsule is not expected to prov ide an y clinical benefit to healthy participants.
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Prim ary: Prim ary: 
To demonstrate bioequivalence betw een 
prazosin HCL 1 and 2 mg capsules 
manufactured at the proposed site (Ascoli) 
versusprazosin HCl 2 mg capsules 
manufactured at current site (Barceloneta) 
under fasting conditions in healthy adult 
participants. 
To demonstrate bioequivalence betw een 
prazosin HCl 5 mg capsules manufactured at 
the proposed site (Ascoli) v ersusprazosin HCl 
5 mg capsules manufactured at current site 
(Barceloneta) under fasting conditions in 
healthy adult participants.AUC lastand C maxof prazosin.
Secondary: Secondary: 
To evaluate the safety and tolerability of 
prazosin HCl capsules.AUC inf(if data permit), t ½(if data permit) and 
Tmaxof prazosin.
Adverse events (AEs).
4.STUDY DESIGN
4.1.Overall Design
This will be a 2 Cohort , open-label, randomized, single dose stud y in healthy adult male 
and/or female participants.
Cohort 1 will be crossover with 3 treatments , 3 period s, 6 sequences. Cohort 2 will be 
crossover with 2 treatments , 2 periods, 2 sequences.
Approximately  36 participants will be enrolled in each Cohort 1 and Cohort 2.Participants
enrolled in Cohort 1 will not be eligible for Cohort 2 and vice versa. Dropouts for non- safety  
reasons may  be replaced at the discretion of the sponsor and investigator. Participants in 
Cohort 1 will be assigned to 1 of the 6 sequences according to a computer -generated 
randomization schedule (see Table 2 ).Participants in Cohort 2 will be assigned to 1 of the 2 
sequences according to a computer- generated randomization schedule (see Table 3).

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 20Table 2. Sequences for Cohort 1
Sequence N Period 1 Washout 
PeriodPeriod 2 Washout 
PeriodPeriod 3
1 6 Treatment A At least
7 daysTreatment B At least
7 daysTreatment C
2 6 Treatment B Treatment C Treatment A
3 6 Treatment C Treatment A Treatment B
4 6 Treatment A Treatment C Treatment B
5 6 Treatment B Treatment A Treatment C
6 6 Treatment C Treatment B Treatment A
Treatment A: Prazosin HCL 1 x 2 mg capsule manufactured at the current site (Barceloneta) under fasting 
conditions (Reference).
Treatment B: Prazosin HCl 1 x 2 mg capsule manufactured at the proposed site (Ascoli) under fasting 
conditions (Test1).
Treatment C: Prazosin HCl 2 x 1 mg capsule manufactured at the proposed site (Ascoli) under fasting 
conditions (Test2 ).
Table 3.Sequences for Cohort 2
Sequence N Period 1 Washout Period Period 2
1 18 Treatment D At least 7 days Treatment E
2 18 Treatment E Treatment D
Treatment D: Prazosin HCl 1 x 5 mg capsule manufactured at the current site (Barceloneta) under fasting 
conditions (Reference).
Treatment E : Prazosin HCl 1 x 5 mg capsule manufactured at the proposed site (Ascoli) under fasting 
conditions (Test).
There will be a minimum 7 day washout period between successive doses (ie, administration 
of subsequent doses of study  medication will not occur until at least 7 day s after the previous 
dose of study  medication).
Screening evaluation will occur w ithin 28 day s prior to the first dose of study  medication.
Day -1 is defined as the day  prior to the first day  of dosing (Day 1) in each period.
Participants will be admitted to the clinical research unit (CRU) on Day  -1 and will remain 
confined in the CRU for approximately  3 day s and 2 nights during each period until the 
collection of the 24 hour PK sample .Participant s may  remain at the CRU between study  
periods at the discretion of the investigato r.The total duration of participation from the 
Screening 
Visit to Discharge will be approximately  6 weeks , and from the Screening Visit to 
Follow -up will be approximately  11 weeks .
On Day  1 of each period, participants will receive a single dose of investigational product as 
per randomization schedule . Study treatments will be administered with approximately  
240mL of ambient temperature water under fasting conditions (overnight fast and no food 
until 4 hours after dosing). Water will be allowed without restriction until 1 hour prior to 
dosing andmay be consumed without restriction beginning 1 hour after dosing.

CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 21Blood samples for the analysis of prazosin in plasma will be obtained predose (immediately 
prior to dosing) and postdose as outlined in Schedule of Activities (SoA) table.
Tolerability and safety will be assessed for all treatments by monitoring AEs.4.2. Scientific Rationale for Study Design
This study is intended to be a pivotal BE study to support the transfer of manufacturing 
operations for prazosin HCl capsules (1 mg, 2 mg and 5 mg) from Barceloneta to Ascoli with the associated process changes and regulatory registration.
The study design follows the United States (US) Food and Drug Administration (FDA)
product specific BE guidance for prazosin hydrochloride oral capsules.
4
4.2.1. Choice of Contraception/Barrier Requirements
Human reproductive safety data are not available for prazosin HCl. Therefore, the use of a 
highly effective method of contraception is required (see Appendix 4 ).
4.2.2. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further analyses which may, for 
example, provide greater understanding of the study intervention.
 
 
 
 
 
 
  
 
 CCI
CCI
CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 22 
  
 
 
 
 
 
 
 
 
 
 
4.4. End of Study Definition
A participant is considered to have completed the study if he/she has completed all phases of 
the study including the last visit or the last scheduled procedure shown in the SoA.
The end of the study is defined as the date of the last visit of the last participant in the study 
or last schedule procedure shown in the SoA for the last participant in the study.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.CCI
CCI
CCI
CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 235.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1. P articipants must be 18 to 55 y ears of age, inclusive, at the time of signing the I CD.
Refer to Appendix 4forreproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Male and female participants who are overtl y healthy as determined b y medical 
evaluation including medical history , full phy sical examination, vital signs, 12
-lead 
electrocardiogram (ECG ), and/or clinical laboratory  tests.
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations , and other study  procedures.
Weight:
4.BMI of 17.5 to 30.5 kg/m2; and a total body  weight >50 kg (110 lb).
Informed Conse nt:
5. Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing) .
2.Any condition possibly  affecting drug absorption (eg, gastrectomy ).
3.History  of HIV infection, hepatitis B, or hepatitis C; positive te sting for HIV, HBsAg, 
HBcAb or HCVAb. Hepatitis B vaccination is allowed.
4.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 24situations relate d to COVID -19 pandemic (eg. Contact with positive case, residence, 
or travel to an area with high incidence) that may  increase the risk of study 
participation or , in the investigator’s judgment, make the participant inappropriate for 
thestudy .
Prior/Conco mitant Therapy:
5.Use of prescription or nonprescription drugs and dietary  and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention .(Refer to 
Section 6.8Concomitant Therap y for additional details).
6.Current use of any prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 6.8Concomitant 
Therap y.
Prior/Concurrent Clinical Study Experience:
7.Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of study  intervention
used in this study  (whichever is longer ).
Diagnostic Assessments:
8.A positive urine drug test .
9.Screening supine BP ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least 5minutes of supine rest. If BP is ≥140 mmHg (s ystolic) or ≥90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility .
10.Baseline standard 12- lead ECG thatdemonstrates clinically relevant abnormalities that 
may affect participant safety or interpretation of study results (eg, baseline QTc F
interval >450 msec, complete LBBB, signs of an acute or indeterminate- myocardial
infarction, ST interval and T -wave changes suggestive of my ocardial ischemia, 
second or third- degree AVblock, or serious bradyarrhy thmias or tachy arrhythmias). 
If the baseline uncorrected QT interval is >450 msec, this interval should be 
rate--corrected using the Fridericia method and the res ulting QTcF should be used for 
decision making and reporting. If QTc Fexceeds 450 msec, or QRS exceeds 
120msec, the ECG should be repeated 2 more times and the average of the 3 QTcFor 
QRS values should be used to determine the participant’s eligibility . 
Computer -interpreted ECGs should be overread b y a physician experienced in 
reading ECGs before excluding a participant.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 2511. Participants with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary : 
AST or ALT level ≥1.5 × ULN;
Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's 
syndrome may  have direct bilirubin measured and would be eligible for t his study  
provided the direct bilirubin level is≤ ULN.
Other Exclusions:
12.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5(male) and 4 (fema le) or more alcoholic drinks in about 2 hours . As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit=
8ounces (240 mL) beer, 
1ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
13.Blood donation (excluding plasma donations) of approximately  1pint (500 mL) or 
more within 60 days prior to dosing .
14.Use of tobacco- or nicotine -containing products in excess of the equivalent of 
5cigarettes per day .For chewing tobacco, one chew is equivalent to approximately  
2-3 cigarettes, so participant s would be limited to 2 or less chews per day .
15.History  of sensitivity  to prazosin hy drochloride or any  of the components in the 
formulation of the study  products.
16.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol
.
17.Investigator site staff or Pfizer employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  the investigator, and their respective family  
members .
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PK sample.
Water is permitted until 1 hour prior to study  intervention administration. Water may  
be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 26(except grapefruit or grapefruit- related citrus fruit juices —see below) may  be 
consumed with meals and the evening snack.
Lunch will be provided approximately  4
hours after dosing.
Dinner will be provided approximately  9to 10 hours after dosing.
An evening snack may  be permitted.
Participants will refrain f rom consuming red wine, grapefruit ,or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of study  intervention until collection of the final PK blood sample.
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Participants will abstain from caffeine -containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study  period.
Participants will abstain from alcohol for 24 hours prior to admission to the clinical 
research unit (CRU) and continue ab staining from alcohol until collection of the final 
PK sample of each study  period. Participants may  undergo an alcohol breath test or 
blood alcohol test at the discretion of the investigator.
Participants will abstain from the use of tobacco -or nicotine -containing products for 
24 hours prior to dosing and during confinement in the CRU.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted;
In order to standardize the conditions on PK sampling day s, participants will be 
required to refrain from ly ing down (except when required for BP, pulse rate, and 
ECG mea surements), eating, and drinking beverages other than water during the first 
4hours after dosing;
If participant is lay ing down, to avoid the situation of sudden hy potension and 
dizziness, he/she should stand up graduall y such as sitting before standing u p. 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 275.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitt ed list of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that t he participant has been instructed in its 
consistent and correct use. At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant ’s affirmation in the participant ’s 
chart ( participant s need to affirm their consistent and correct use of at least 1 of the sele cted 
methods of contraception) considering that their risk for pregnancy  may  have changed since 
the last visit . In addition, the investigator or designee will instruct the participant to call 
immediately  if the selected contraception method is discontinued or if pregnancy  is known or 
suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention . Screen fail ure data are 
collected and remain as source and are not reported on the CRF .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  
not be rescreened.
6.STUDY INTERVENTION (S) AND CONCOMITANT THERAPY
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervent ion refers to investigational product
.
6.1.Study Intervention(s) Administered
For the purposes of this protocol, study  intervention refers to prazosin HCl capsules.
Prazosin HCl 2 mg and 5 mg capsules, manufactured at Pfizer Pharmaceutical, Barceloneta, 
Puerto Rico and prazosin HCl 1 mg, 2 mg and 5 mg capsules, manufactured at Pfizer 
Pharmaceutical, Ascoli, Italy  will be supplied to the CRU along with individual dosing 
containers for unit dosing.
Pivotal BEstudy  capsules will be supplied to the CRU in multidose labeled containers (in 
sufficient number to allow unopened containers to be kept as retains).
6.1.1. Administration
Following an overnight fast of at least 10 hours, participant s will receive study  interven tion
at approximately  0800 hours (plus or minus 2 hours). Investigator site personnel will 
administer study  intervention during each period with ambient temperature water to a total 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 28volume of approximately 240 mL. Participant s will swallow the study  interv ention whole, 
and will not manipulate or chew the study  intervention prior to swallowing. 
In order to standardize the conditions on PK sampling day s, all participant s will be required 
to refrain from ly ing down (except when required for BP, pulse rate , and ECG 
measurements), eating, and drinking beverages other than water during the first 4 hours after 
dosing.
6.2.Preparation , Handling , Storage , and Accountability
1.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documente d for 
all site storage locations upon return to business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning th e stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded by  the storage 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.
7.Further guidance and information for the fi nal disposition of unused study  
interventions are provided in the IP manual .All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 29investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y Pfizer
8. All pivotal BE retained capsules should be stored by  the investigator site or with a 
third- party vendor. Sample retention is the r esponsibility  of the entity  performing the 
BE stud y.
Upon identification of a product complaint, notify the sponsor w ithin 1 business day  of 
discovery .
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by qualified 
staff. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  qualified staff member(s) to a healthcare provider, 
participant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may  use alternative terms for the se activities.
Capsules will be prepared at the CRU in the individual dosing containers by  2operators, 1 of 
whom is an appropriatel y qualified and experienced member of the stud y staff (eg, ph ysician, 
nurse, ph ysician’s assistant, nurse practitioner, pharmacy  assistant/technician, or pharmacist).
The capsules will be provided in unit dose containers and labeled in accordance with Pfizer 
regulations and the clinical site’s labeling requirements. 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. All ocation to Study Intervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participant s are enrolled.
The investigator will assign participant numbers to the participant s as they  are screened for 
the study . Pfizer will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the stud y treatment regimen 
assigned to the corresponding ran domization number.
6.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF. 
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study  intervention was ingested.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 306.5. Dose Modification
Does modification is not applicable to this study .
6.6.Continued Access to Study Intervention A fter the End of the S tudy
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of study  intervention greater than 5 mg within a 24 -hour time period 
will be considered an overdose.
The sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact the medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 h alf-lives or 28 calendar day s after the overdose of study  intervention 
(whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Pfizer Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 1 day from the date of the last dose of 
study  intervention if requested by  the medical monitor (determined on a case -by-case 
basis).
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety  or the overall results of the study may
 be permitted on a case -by-case basis 
following approval by  the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤1g/day .
Females using hormonal contraceptives or taking hormone replacement therap y may be 
eligible to participate in this study  if they  are willing to discontinue therapy at least 28 days 
prior to the first dose of study  treatment and remain off hormonal therap y for the duration of 
the study . Depo -Provera®must be discontinued at least 6 months prior to the first dose of 
study  treatment.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 31All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of study  interventi on will be 
documented as a prior treatment. Treatments taken after the first dose of study  intervention 
will be documented as concomitant treatments.
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following
significant change in vital signs or 
adverse event. 
If study  intervention is permanentl ydiscontinued, the participant will not remain in the study  
for further evalu ation. See the SoA for data to be collected at the time of discontinuation of 
study  intervention.
7.2. Participant Discontinu ation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further study  procedures ;
Lost to follow -up;
Death ;
Study  terminated by sponsor ;
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y furthe r evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.
The participant will be permanentl y discontinued from the study intervention and the study  at 
that time.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 32If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected befo re such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously  authorized by  the participant to provide this 
information. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow --up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow --up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  asappropriatel y directed in 
accordance with local law.
7.3.Lost to Fol lowup 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact with the participant (where pos sible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 338.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific pr ocedures.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, a s applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unex pected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll from a n earlier Cohort /group 
may be used in a subsequent Cohort /group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteria for this study . In 
addition, other clinical assessments or specimen collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time the re may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol --require d test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be inform ed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 34The total blood sampling volume for individual participant s in this study  is approximatel y 
260mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified b y Pfizer, provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 
56 consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
Not applicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time durin g the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the 
listening to the lungs, blood pressure, pulse rate and cardiac auscultation , and 
participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. 
Participant s must remove shoes, bulky  layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. The site should ensure the regular calibration of their weight 
scale according to manufacturer’s instruction.
Physical examination findings collected during the study  will be considered sourc e data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appe ndix 3 ) must be reported according to the processes in 
Sections 8.3.1 to 8.3.3.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 358.2.2. Vital Signs
Supine BP will be measured with the participant ’s arm supported at the level of the heart, and 
recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm 
(preferabl y the dominant arm) will be used throughout the study. Participant s should be 
instructed not to speak during measurements. 
The same properl y sized and calibrat ed BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary
, to ensure appropriate collection of safety  data.
The procedure for collecting postural or orthostatic data will be:
Assess BP after the participant is in the supine position for a minimum of 5 minutes;
Have the participant stand up for 2 minutes;
Assess BP after the participant is in the standing position for approximately  
2minutes.
Orthostatic hy potension is defined as a decrease of 
≥20mmHg for s ystolic BP or 
≥10mmHg for diastolic BP 2 minutes after standing from a supine position. Orthostatic 
hypotension may  be symptomatic or as ymptomatic. Sy mptoms of orthostatic hy potension are 
those that develop upon assuming the erect posture from a supine position and may include: 
lightheadedness, dizziness, blurred vision, weakness, fatigue, cognitive impairment, nausea, 
palpitations, tremulousness, headache, and/or neck ache.
If a participant has s ymptoms suggestive of orthostasis, but not documented orthostatic 
hypotens ion, repeated measurements of supine/standing BP should be obtained. Lesser 
degrees of BP reduction may  still be considered clinically  significant if the participant 
becomes s ymptomatic upon standing, especiall y in the presence of a significant increase in
pulse rate ( ≥30beats per minute [bpm]).
8.2.3. Electrocardiograms
Supine 12-lead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be collected 
at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex . Alternative lead placement methodology using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5 minutes in a supine position. 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 36In some cases, it may  be appropr iate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolong ed, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency. All protocol -required laboratory  assessments, as defined in 
Appendix 2 , must be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements m ay be obtained at any  time during the study  
to assess an y perceived safet y issues
.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF .
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values consid ered clinically  significantl y abnormal during 
participation in the study  or within 28 day s after the last dose of stud y intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -up assessments in the event of potential 
drug-induced liver injury.
Participant s may  undergo random urine drug testing at the discretion of the investigator.
Drug testing conducted prior to dosing must be negative for participant s to receive study  
intervention . 
8.2.5. COVID -19 specific assessments 
Participants will be tested for SARS -COVID -19 infection by  PCR prior to being admitted to 
the clinic and at each visit for confinement and a subsequent COVID -19 test will be 
perfor med after 4 day s (i.e. upon completion of 4 x 24 hours in house), or if they  develop 
COVID -19 like s ymptoms. COVID -19 questionaire and temperature check will be pefromed 
per the SoA . Additional testing may  be required by  local regula tions or by  the Principal 
Investigator.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 378.2.6. Pregnancy Testing 
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times listed in the SoA .
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant ’sreceiving the study  intervention . Pregnancy  tests w ill also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  also be 
repeated if requested b y IRBs/ ECs or if required by loca l regulations. If a urine test cannot 
be confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is required. In 
such cases, the participant must be excluded if the serum pregnancy  result is positive .
8.3.Adverse Events ,Serious Adverse Events ,and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for cla ssification as an SAE or caused the participant to discontinue 
thestudy  (see Section 7.1 ). 
During the active collection period as described in Section 8.3.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of 28 calendar days after the last administration of the study  intervention .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 38If the participant withdraws from the study  and also with draws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues study because of an AE 
or SAE, the AE or SAE must be recorded on the CRF and the SAE reported using the CT 
SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, a t any time after a participant has completed the study , and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to Pfizer using the CT SAE Report Form.
8.3.1.1.
Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  on the CT SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1 , will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observ ed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the inves tigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 39possible causality .Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further informatio n on follow -up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB
s/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact with or exposure to the study
 intervention. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for en vironmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such e xposure to the study  intervention under study  are reportable to Pfizer Safet y 
within 24 hours of investigator awareness.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A male 
participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 40A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmenta l exposure. Below are examples of 
environmental EDP :
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by ingestion .
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  ingestion then exposes his female partner prior to or around the 
time of conception .
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this infor mation to Pfizer Safety on the CT SAE Report Form and an EDP 
Supplemental F
orm, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until 24 hours 
after the last dose.
If EDP occur s in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown out come. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neo nate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion i nclud ingmiscarriage and missed abortion;

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 41Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the in fant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preter m infants to identify  developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source docum ents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by ingestion .
The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environ mental exposure, the exposure information does 
not pertain to the participant enrolled in the stud
y, so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE i s reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 24 
hours of the investigator’s awareness 
using the CT SAE Report Form regardless of whether 
there is an associated SAE. Since the information about the occupational exposure does not 
pertain to a participant enrolled in the study , the information is not recorded on a CRF; 
however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 428.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not Applicable.
8.3.8. Adverse Events of Special Interest
Not Applicable.
8.3.8.1. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not Applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by the wrong participant , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report
Form to Pfizer Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .

CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 43Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics 
Blood samples of approximately 4 mL, to provide approximately 1.5 mL plasma, will be 
collected for measurement of plasma concentrations of prazosin as specified in the SoA.
Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by the sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time (eg, within 6 minutes of a 60-minute sample) relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and data collection tool (eg, CRF/DCT). Collection of samples more than 10 hours after dose administration that are obtained ≤1 hour away from the nominal 
time relative to dosing will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and data collection tool (eg, CRF/DCT). 
 
Genetic analyses will not be performed on these plasma samples. Participant confidentiality 
will be maintained.
Samples collected for measurement of plasma concentrations of prazosin will be analyzed 
using a validated analytical method in compliance with applicable standard operating procedures (SOPs).
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor.On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.CCI
CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 448.5.Genetics
8.5.1. Specified Gen etics
Genetics (specified anal yses) are not evaluated in this study .
8.5.2. Retained Research Samples for Genetics
A 4 mL  blood sample optimized for DNA isolation Prep D1 will be collected according to 
the SoA ,as local regulations and I RBs/ECs allow.
Retained Research Samples may be used for research related to thestudy  intervention (s). 
Genes and other analy tes (eg ,proteins, RNA, nondrug metabolites) may  be studied using the 
banked samples. 
See Appendix 5for i
nformation regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in Lab Manual.
8.6.Biomarkers
Biomarkers are not evaluated in this study .
8.7.Immunogenicity Assessme nts
Immunogenicit y assessments are not included in this study .
8.8.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP, which will be maintained b y the sponsor. The 
SAP may  modify  what is outlined in the protocol where appropriate; ho wever, an y major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
The alternative hy pothesis of bioequivalence (H1: L<=T-R<=U), and the null 
hypothesis of inequivalence (Ho: T-R<L orT-R>U) can be expressed as the 
following 2 separate one -sided hy potheses: 
HoA: T-R<L
H1A: L<=T-R
HoB: T-R>U
H1B: T-R<=U

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 45where T and R represent the average bioavailability  on a log scale for the Test and 
Reference products respectively  and [L,U] defines the bioequivalence range.
Bioequivalence of the Test treatment to Reference treatment will be concluded if the 
90% confidence inter vals for the ratios of adjusted geometric means for prazosin AUC lastand 
Cmaxfall entirely  within the acceptance region of (80%, 125%).
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis 
SetDescription
Enrolled /Randomly  
assigned to stud y 
interventionParticipants will be randomized into the study  provided they  
have satisfied all participant eligibility  criteria.
PK concentration 
populationAll participants randomized and treated who have at least 1 
concentration in at least 1 treatment period.
Safety All participants randomly  assigned to study  intervention and 
who take at least 1 dose of investigational product.
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. Primary Endpoint(s)
9.3.1.1. Determination of Pharmaco kinetic Parameters
Pharmacokinetic parameters will be derived from the concentration -time profiles as shown in 
Table 5.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 46Table 5. PK Parameters
Parameter Definition Method of Determ ination
AUC last Area under the plasma 
concentration -time curve from 
time zero to the time of the last 
quantifiable concentration (C last).Linear -log trapezoidal method.
AUC inf Area under the plasma 
concentration -time curve from 
time zero extrapolated to infinite 
time.AUC last+ (C last*/k el),
where C last* is the predicted 
plasma concentration at the last 
quantifiable time point estimated 
from the log -linear regression 
analysis.
Cmax Maximum plasma concentration. Observed directly from data.
Tmax Time to first occurrence of Cmax. Observed directly from data as 
time of first occurrence.
t½ Term inal elimination half -life. Ln(2)/k el,
where k elis the terminal phase rate 
constant calculated by a linear 
regression of the log linear 
concentration -time curve. Only 
those data points judged to 
describe the terminal log -linear 
decline will be used in the 
regression.
Actual PK sampling times will be u sed in the derivation of PK parameters.
9.3.2. Statistical Analysis of Pharmacokinetic Parameter
Pharmacokinetic and statistical analy sis will be performed for prazosin. Data from 2 Cohort s 
will be anal yzed separately .
The PK parameters AUC last, AUC inf, Cmax, Tmax, and t ½ will be summarized descriptivel y by 
analyte and treatment. For AUC last, AUC infand C max parameters, individual data and 
geometric mean will be plotted with box plots by  analy te and treatment for each parameter.
Plasma concentration data will be listed and summarized descriptivel y by analyte, PK 
sampling time and treatment. Individual participant and summary  profiles (mean and median) 
of the plasma concentration- time data will be plotted against anal yte by treatment. Mean and 
median profiles will be presented on both linear -linear and log -linear scales. For summary  
statistic and summary  (mean and median) plots by sampling time, the nominal PK sampling 
time will be used. For individual participant plots by  time, the actual PK sampling time will 
be used.
Cohort 1:
Natural log transformed PK parameters ( AUC inf,AUC last, and C max) will be anal yzed using a 
mixed effect model with sequence, period and treatment as fixed effects and participant
within sequence as a random effect. Estimates of the adjusted mean differences 
(Test –Reference) and the corresponding 90% confidence intervals will be obtained from the 
model. The adjusted mean differences and the 90% confidence intervals for the differences 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 47will be exponentiated to provide estimates of the ratio of adjusted geometric means 
(Test/Reference) and the 90% confidence intervals for the ratios.
For primary  objective, bioequivalence of the Test treatments (Treatment B and Treatment C) 
relative to Reference treatment (Treatment A) will be concluded if the 90% confidence 
intervals for the ratio of adjusted geometric means of Test treatments (Treatment B and 
Treatment C) relative to Reference treatment (Treatment A) for AUC inf(if data permit ), 
AUC lastand C maxfall wholly  within (80%, 125%).
Cohort 2:
Natural log transformed PK parameters ( AUC inf,AUC last, and C max) will be anal yzed using a 
mixed effect model with sequence, period and treatment as fixed effects and participant
within sequence as a random effect. Estimates of the adjusted mean difference s 
(Test –Reference) and the corresponding 90% confidence intervals will be obtained from the 
model. The adjusted mean differences and the 90% confidence intervals for the differences 
will be exponentiated to provide estimates of the ratio of adjusted geom etric means 
(Test/Reference) and the 90% confidence intervals for the ratios.
For primary  objective, b ioequivalence of the Test treatment (Treatment E) relative to 
Reference treatment (Treatment D) will be concluded if the 90% confidence intervals (CI) 
forthe ratio of adjusted geometric means of Treatment E (5 mg capsule, Ascoli) relative to 
Treatment D (5 mg capsule, Barceloneta) for AUC inf (if data permit), AUC lastand C max, fall 
wholly  within (80%, 125%).
9.3.3. Safety analyses
All safet y anal yses will be performed on the safet y population.
The safet y data will be described and summarized in accordance with the Sponsor’s Data 
Standards.
AEs, ECGs, BP, pulse rate, and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study to evaluate the safet y of participants. Any clinical 
laboratory , ECG, BP, and pulse rate abnormalities of potential clinical concern will be 
described. Medical history  and phy sical examination and neurological examination 
information, as applicable, colle cted during the course of the study  will be considered source 
data and will not be required to be reported, unless otherwise noted. However, any  untoward 
findings identified on physical and/or neurological examinations conducted during the active 
collectio n period will be captured as AEs, if those findings meet the definition of an AE.
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be considered source data, and will not be re quired to be 
reported, unless otherwise noted. Demographic data collected at screening will be reported.
9.3.4. Other Analyse (s)
There are no other analy ses included in this study .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 489.4.Interim Analyses
No formal interim anal ysis will be conducted for this study . As this is an open -label
study ,the sponsor may  conduct unblinded reviews of the data during the course of the study  
for the purpose of safet y assessment, facili tating PK/PD modeling, and/or support ingclinical 
development. 
9.5.Sample Size Determination
Cohort 1:
A sample size of 30 participants will provide at least 95% power that the 90% confidence 
interval for the ratio of Test to Reference treatment for both AUC lastand C maxof prazosin, 
individually  will lie within the acceptance region of (80%, 125%). Consequently , this study  
will have approximately  90% overall power to demonstrate bioequivalence of the Test 
treatment to the Reference treatment [ie, equivalence for both AUC and Cmax], where overall 
power for the study  is based on the product of the individ ual powers of the parameters of 
interest. This estimate is based on the assumption that the true ratio between Test and 
Reference treatments for both AUC lastand C maxis 0.95 and also assumes within- participant
standard deviations of 0.198 for both log eAUC lastand log eCmax, as obtained from the 
literature.
To allow for dropouts, 36 participants will be enrolled in order to have 30 PK evaluable
participants. Dropouts for non -safety  reasons may be replaced at the discretion of the sponsor 
and investigator .
Cohort 2:
A sample size of 32 participants will provide at least 95% power that the 90% confidence 
interval for the ratio of Test to Reference treatment for AUC lastand C maxof prazosin, 
individually , will lie within the acceptance region of (80%, 125%). Consequently , this study  
will have approximately  90% overall power to demonstrate bioequivalence of the Test 
treatment to the Reference treatment [ie, equivalence for both AUC and Cmax], where overall 
power for the study  is based on the product of the ind ividual powers of the parameters of 
interest. This estimate is based on the assumption that the true ratio between Test and 
Reference treatments for both AUC lastand C maxis 0.95 and also assumes within- participant
standard deviations of 0.198 for both log eAUC lastand log eCmaxrespectively, as obtained 
from the literature. 
To allow for dropouts, 36 participants will be enrolled in order to have 32 PK evaluable
participants. Dropouts for non -safety  reasons may be replaced at the discretion of the sponsor 
and investigator .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 4910. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I C
D, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor ,submitted to an I RB/EC 
by the investigator, and reviewed and approved by  the IRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device res earch (if applicable), and all other applicable local 
regulations .
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any  area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 50In addition, the investigator will inform Pfize r immediately of an y urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate r egulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant or his/her legally  authorized representative and answer 
all questions regarding the study . The participant or his/her legall y authorized representative 
should be given su fficient time and opportunity  to ask questions and to decide whether or not 
to participate in the trial.
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, I CH guidelines, privacy  and data 
protection requirements, where applicable, and the I RB/EC or study  center.
The investigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of the study , the sharing of 
data related to the study ,
and possible risks associated with participation, including the risks 
associated with the processing of the participant ’s personal data. 
The participant or his or her legall y authorized representative must be informed that his/her 
personal stud y-related data will be used by  the sponsor in accordance with local data 
protection law. The level of disclosure must also be explained to the participant or his or her 
legally  authorized representative .
The participant or his or her legall y authorized representative must be informed that his/her 
medical records may  be examined by  Clinical Quality  Assurance auditors or other authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  inspectors 
from regulatory  authorities.
The investigator further must ensure that each study  participant or his or her legall y 
authorized representative is fully informed about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her personal data.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 51The medical record must include a statement that written informed consent was obtained 
before the partic ipant was enrolled in the study and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.
Participants or his or her legally authorized representative must be reconsented to the most 
current version of the IC D(s) during their participation in the study .
A cop y of the IC D(s) must be provided to the participant or the participant’s legall y 
authorized representative.
10.1.4. Data Protection
All parties will comply  with all applicable laws, incl uding laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password -protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study  site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
10.1.5.1. Data Monitoring Committee 
This study  will not use a DMC.
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 52In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT
Pfizer posts clinical trial r esults on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, s
ample CRF s, and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01Janua ry2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data sharing
Pfizer provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scient ific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 53be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.7. Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details des cribing strategy, including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  the sponsor or designee.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the 
sponsor or its agents to prepare the investigator site for the inspection and will allow 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 54the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identi fied 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous 
medical records or transfer records, depending on 
the study . Also, current medical records must be available.
In this stud y, the CRF will serve as the source document. A document must be available at 
the investigative site that identifies those data that will be recorded on the CRF and for which 
the CRF will be the source document.
Definition of what constitutes source data and its origin can be found in data collection 
guidelines , which is maintained by  the sponsor .
Description of the use of the computeriz ed sy stem is documented in the Data Management 
Plan, which is maintained by  the sponsor.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accor dance with the currently approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 55completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at any  time upon notification to the CRO if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.
Reasons for the earl y closure of a stud y site b y the sp onsor may  include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  the investigator ;
Discontinuation of further study  intervention development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provid ed for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments , and the investigator will, on request, remove an y previou sly undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the s tudy, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply
 with the requirements for publicatio n of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 56sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator will be designated b y mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor's appropriately qualified medical personnel for the 
study is documented in the study  contact list located in the SToD sy stem.
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact Card (ECC) at 
thetime of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) Pfizer Call C enter number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  healthcare 
professionals not involved in the research stud y only , as a means of reaching the investigator 
or site staff related to the care of a participant. The Pfizer Call Center number should only  be 
used when the investigator and site staff cannot be reached. The Pfizer Call Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 5710.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  the clinical laboratory ,or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Table 6. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Uric acid
Albumin
Total proteinLocal Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
Urine drug 
screeninga
Laboratory:
Microscopy and 
CulturebCOVID -19 testing
At screen ingonly:
FSHc
Pregnancy test ( -hCG )d
Hepatitis B surface 
antigen
Hepatitis C antibody
Human 
immunodeficiency virus
a.The minimum requirement for drug screening includes cocaine, THC, opiates/opioids, 
benzodiazepines, and amphetamines (others are site and study specific).
b.Only if urine dipstick is positive for blood, protein, nitrites ,or leukocyte esterase.
c.For confirmation of post meno pausal status only.
d.Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/EC. Serum or urine -hCG for female participants of childbearing potential.
The investigator must review the laboratory  report, document this review, and record an y 
clinically  relevant changes occurring during the study in the AE section of the CRF.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 5810.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical ch emistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any 
abnorma l laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency and/or i ntensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self- harming inte nt. Such overdoses should be reported regardless of 
sequelae.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 59Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing ho spitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalization or fulfills any  other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or w as 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 60d.Results in persistent or significant disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,
such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth de fect
f.Is a suspected transmission via a Pfizer product of an infectious agent, 
pathogenic or non -pathogenic, is considered serious.
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed t o a Pfizer product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases b y 
pharmacovigilance personnel. Such cases are also considered for reporting a s 
product defects, if appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by the investigator in 
deciding whether SAE reporting is appropriate in other situations ,such as 
significant medical events that may  jeopardize the participant or may  require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 61It should be noted that the CT SAE Report Form for reporting of SAE in formation is not 
the same as the AE page of the CRF. When the same data are collected, the forms must 
be completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure 
to the product under 
study  to a non -
participant (not 
involving EDP or EDB ).None. Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
Pfizer Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE 
Report F orm. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational 
exposure are reported to Pfizer Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 62It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF p age.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records befo
re submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AEor SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, ma naging money , etc.
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting 
self care ADL. Self care ADL refers to bathing, dressing and undressing, feed ing 
self, using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
Theinvestigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that the re are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 63Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to stud y intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for 
marketed products, in his/her assessment.
For each AE or SAE, the investigator must document i
n the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor .
The investigator may  change his/her opinion of causality  in light of follow -up 
inform ation and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  intervention ” for 
reporting purposes, as defined by  the sponsor . In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record this causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically  indicated or as 
requested b y the sponsor ,to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laborator y tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a copy of any 
postmortem findings, including histopathology .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 64New or updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 
hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic da ta collection tool 
will be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic data collec tion 
tool has been taken off -line, then the site can report this information on a paper 
SAE form (see next section) or to Pfizer Safet y by telephone.
SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working , notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 
courier service.
Initial not ification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 6510.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 8 day safter the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproduct ive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a condom may
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently  pregnant.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductiv e Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 
1of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly
 effective (with a failure 
rate of <1% per year), with low user dependency, as described below during the 
intervention period and for at least 28 day safter the last dose of study  intervention ,
which corresponds to the time needed to eliminate any  reproductive safet y risk of the 
study  intervention(s) . The investigator should evaluate the effectivene ss of the 
contraceptive method in relationship to the first dose of study intervention.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 66The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an early undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a men strual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examinatio n, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 6710.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion (eg, bilateral tubal ligation) .
5.Vasectomized partner .
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method o f contraception 
should be used. The s permatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation .
Oral;
Intravaginal;
Transdermal ;
Injectable .
7.Progestogen -only hormone contraception associated with inhibition of ovulation .
Oral;
Injectable .
8.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterose xual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 68evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
One of the following effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 6910.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the genetic research may  benarrow (eg, 1or more candidate genes ) or
broad (eg,the entire genome ),as appropriate to the scientific question under 
investigation.
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to study  intervention or study  interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in the CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  repo rt.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Retained samples will be stored indefinitely  or for another period as per local 
requirements.
Participant s may  withdraw their consent for the storage and/or use of their Retained 
Research Samples at an y time by  making a request to the investigator; in this case, 
any remaining material will be destroy ed. Data already  generated from th e samples 
will be retained to protect the integrit y of existing anal yses.
Samples for genetic research will be labeled with a code. The key  between the code 
and the participant ’s personally  identify ing information (eg ,name, address) will be 
held 
securely at the study site.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 7010.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and the refore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
LFTs are not required as a routine safety  monitoring procedure in this study . However, 
should an investigator deem it necessary  to assess LFTs because a participant presents with 
clinical signs/s ymptoms, such LFT results should be managed and followed as described 
below.
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pically  occurs while AST/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values will be elevated within 
the same lab oratory sample). In rare instances, by the time TBili elevations are detected, 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI.
Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been e xcluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, a s needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 71Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; an y case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBili for suspected Hy ’s law 
cases , additional labor atory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
t
esting, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  itself or as a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusi on, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample sfor acetami nophen /paracetamol drug and/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A poten
tial DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 7210.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by60msecfrom 
baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’
duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive 
ventricular complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 msec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 ms ec).
New -onset right bundle b ranch block (QRS >120 msec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with 1 or more pauses of at le ast 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 73Ventri cular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR > 40bpm to
<100 bpm), and monomorphic/poly morphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, any arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and Pfizer study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 7410.8. Appendix 8:Alternative Measures During Public Emergencies
Thealternative study  measures described in this section areto be followed during public 
emergencies, including the COVID -19 pandemic. This appendix applies for theduration of 
the COVID -19 pandemic globall y and will become effective for other public emer gencies 
only upon written notification from Pfizer. 
Use of these alternative study  measures are expected to cease upon the return of business as 
usual circumstances (including the lifting of an y quarantines and travel bans/advisories). 
10.8.1. Study Intervention
If the safet y of a trial participant is at risk because they cannot complete required evaluations 
or adhere to critical mitigation steps, then discontinuing that participant from study  
intervention must be considered.
10.8.2. Adverse Eve nts and Serious Adverse E vents
If a participant has COVID -19 during the study , this should be reported as an AE or SAE and 
appropriate medical intervention provided. 
It is recommended that the investigator discuss temporary  or permanent discontinuation of 
study  intervention with the study  medical monitor. 

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 7510.10. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
Abs absolute
ADL activities of daily  living
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the curve
AUC last area under the plasma concentration -time curve from time zero to 
the time of the last quantifiable concentration
AUC inf area under the plasma concentration -time curve from time zero 
extrapolated to infinite time
AV atrioventricular
BE bioequivalence
-hCG beta-human chorionic gonadotropin
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
Cmax maximum plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR clinical study  report
CT clinical trial
DC discontinuation
DCT data collection tool
DILI drug-induced liver injury
DMC data monitoring committee
DNA deox yribonucleic acid
EC ethics committee
ECC Emergency  Contact Card
ECG electrocardiogram
eCRF electronic case report form
EDB exposure during birth

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 76Abbreviation Term
EDP exposure during pregnancy
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
f2 similarity factor
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
HBcAb hepatitis B core antibod y
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCl hydrochloride
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HRT hormone replacement therap y
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
IND investigational new drug application
INR international normalized ratio
IP investigational product
IRB institutional review board
IV intravenous
LBBB left bundle branch block
LFT liver function test
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
msec millisecond
N number of participants
PCR polymerase chain reaction
PD pharmacod ynamic(s)
PK pharmacokinetic(s)
PT prothrombin time
PVC premature ventricular complex 
QTc corrected QT
QTcF corrected QT (Fridericia method)
qual qualitative
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event

CP-012299, Prazosin Hydrochloride
A0281006
Final Protocol ,22 February 2021
PFIZER CONFIDENTIAL
Page 77Abbreviation Term
SAP statistical analy sis plan
SARS -CoV -2 severe acute respiratory  syndrome coronavirus 2
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safet y document
SToD study  team on demand
SUSAR suspected unexpected serious adverse reaction
t½ terminal elimination half -life
TBili total bilirubin
THC tetrah ydrocannabinol
Tmax time to first occurrence of C max
ULN upper limit of normal
US United States
USPI United States Package Insert
WBC white blood cell
WOCBP woman of childbearing potential

CP-012299, Prazosin Hydrochloride
A0281006Final Protocol, 22 February 2021
PFIZER CONFIDENTIAL
Page 7811. REFERENCES
1. Minipress®Capsules (prazosin hydrochloride) For Oral Use [prescribing information]. 
New York, NY: Pfizer Inc; Jul 2009. Available from: https://www.pfizer.com/files/products/uspi_minipress.pdf. Accessed: 19 Feb 2019. 
2. Vincent J, Meredith PA, Reid JL, et al. Clinical pharmacokinetics of prazosin – 1985
[abstract]. Clinical Pharmacokinetics. 1985;10: 144-154.
3. Larochelle, P, du Souich P, Hamet P, el al. Prazosin plasma concentration and blood 
pressure reduction [abstract]. Hypertension. 1982;4(1): 93-101.
4. US Food and Drug Administration. Draft Guidance on Prazosin Hydrochloride Oral 
Capsules. December 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Prazosin%20HCl_oral%20capsule_RLD%2017442_RC12-16.pdf. Accessed: 19 Feb 2019
 
 
C
CI